Corcept Therapeutics Inc cash flow statement

In fiscal 2025, Corcept Therapeutics Inc's operations generated $142m of cash; it spent $211,000 on capital projects, leaving free cash flow of $142m. It returned $173m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Corcept Therapeutics Inc: cash flow statement, annual
Fiscal year	2009Dec 2009	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−18	18	61	116	136	152	168	120	127	198	142	110
Depreciation and amortisation	0	0	0	0	1	1	1	1	1	1	1	2
Stock-based pay	2	7	13	24	29	34	43	42	49	61	85	89
Capital spending	—	0	0	0	1	1	0	0	0	2	0	3
Free cash flow	—	18	61	115	135	151	167	120	127	196	142	107
Free cash flow after stock pay	—	11	47	92	106	117	124	77	78	135	57	18
Share buybacks	—	0	0	24	31	10	—	0	0	16	173	42
Shares issued	—	8	7	9	8	23	16	4	6	—	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Corcept Therapeutics Inc: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	73	60	5	44	54	38	−17	34
Depreciation and amortisation	0	0	0	0	−0	0	1	1
Stock-based pay	14	17	22	19	20	21	23	24
Capital spending	2	0	0	0	0	0	0	3
Free cash flow	72	60	5	44	54	38	−17	31
Free cash flow after stock pay	57	43	−17	25	34	18	−40	7

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CORT vs SUPN AXSM vs CORT CORT vs PCRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Corcept Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Corcept Therapeutics Inc.